Lung microangiopathy in diabetes;Mikroangiopatia płucna w przebiegu cukrzycy

Pneumonologia i Alergologia Polska

Volumn 77, Issue 4, 2009, Pages 394-399

  Kuziemski, Krzysztof ^a   Górska, Lucyna ^a   Jassem, Ewa ^a   Madej Dmochowska, Aleksandra ^b  

^a Klinika Alergologii Gda skiego   (Poland)

^b Gdańskiego Uniwersytetu Medycznego ^*  (Poland)

Author keywords

Diabetes mellitus; Lung diffusing capacity for carbon monoxide; Lung microangiopathy; Pulmonary function tests

Indexed keywords

DIABETES MELLITUS; DIABETIC ANGIOPATHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LUNG DIFFUSION CAPACITY; LUNG DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; LUNG DISEASES; PULMONARY DIFFUSING CAPACITY;

EID: 73949157672     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Diabetes Prevention Programme Research Group. New Engl. J. Med. 2002; 346: 393-403.
2. www.who.int/diabetes
3. Tatoń J. Podstawowe zasady kształtowania dobrých usług leczniczych dla pacjentów z cukrzycq: jakościowa perspektywa reformy opieki zdrowotnej. Medycyna Metaboliczna 1999; 3: 8-18.
4. Zalecenia kliniczne dotyczace postȩpowania u chorých na cukrzycȩ, 2008. Diabetologia Praktyczna 2008; 9 (supi. A): 1-49.
5. Luscher T., Creager M., Beckman J. i wsp. Diabetes and vascular disease. Pathophysiology, clinical consequences and medical therapy; Part II. Circulation 2003; 108: 1655-1661.
6. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19: 257-267.
7. Haller H. Endothelial function. General consideration. Drugs 1997; 53 (supl. 1): 1-10.
8. Vlassara H. Recent progress in advanced glycation and products and diabetic complications. Diabetes 1997; 46 (supl. 2): 19-25.
9. De Mattia G., Laurenti O., Fava D. Diabetic endothelial dysfunction: Effect of free radical scavenging in type 2 diabetic patients. J. Diabetes Complications 2003; 17: 30-35.
10. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004; 25: 581-611.
11. Cohen R.A. Dysfunction of vascular endothelium in diabetes mellitus. Circulation 1993; 87: 67-76.
12. Nishikawa T., Edelstein D., Liang Du X. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 689-794.
13. ITnat M.A., Thorpe J.E., Ceriello A. Hypothesis: the "metabolic memory", the new challenge of diabetes. Diabet. Med. 2007; 24: 582-586.
14. Stander J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
15. Resnick H.E., Howard B.V. Diabetes and cardiovascular disease. Annu. Rev. Med. 2002; 53: 245-267.
16. Coppola G., Carradoa E., Muratorib I., Tantilloa R., Vitaleb G. Increased levels of C-reactive protein and fibrinogen influence the risk of vascular events in patients with NIDDM. Int. J. Cardiol. 2006; 106: 16-20.
17. Faresh D. Effects of antidiabetic and antihyperlipidemic agents on C-reactive protein. Mayo Clin. Proc. 2008; 83: 333-342.
18. Schram T.M., Nish Chaturvedi N., Schalkwijk C. i wsp. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: The EURODIAB Prospective Complications Study. Diabetes Care 2003; 26: 2165-2173.
19. Schulze B.M., Rimm B.E., Li T. i wsp. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 2004; 27: 889-894.
20. Jager A., van Hinsbergh V.W.M., Kostense P.J. i wsp. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: The Hoorn Study Arterioscler. Thromb. Vase. Biol. 1999; 19: 3071-3078.
21. Bruno G., Merletti F., Biggeri A. i wsp. Progression to overt nephropathy in type 2 diabetes: The Casale Monferrato Study. Diabetes Care 2003; 26: 2150-2155.
22. Dalquen F. The lung in diabetes mellitus. Respiration 1999; 66: 12-13.
23. Kida K., Utsuyama M., Takizawa T., Thurlbeck W.M. Changes in lung morphologic features and elasticity caused by strepto-zotocin-induced diabetes mellitus in growing rats. Am. Rev. Respir. Dis. 1983; 128:125-131.
24. Popov D., Simionescu M. Alterations of lung structure in experi-mental diabetes, and diabetes associated with hyperlipidaemia in hamsters. Eur. Respir. J. 1997; 10: 1850-1858.
25. Kodolova I.M., Lysenko L.V., Saltykov B.B. Changes in the lungs in diabetes mellitus. Arkh. Fatol. 1982; 44: 35-40.
26. Matsubara T., Hara F. The pulmonary function and histopatho-logical studies of the lung in diabetes mellitus. Nippon Ika Daigaku Zasshi 1991; 58: 528-536.
27. Weynand B., Jonckheere A., Frans A., Rahier J. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration 1999; 66: 14-19.
28. Guazzi M., Iacopo O., Guazzi M.D. Insulin improves alveolarcapilary membrane gas conductance in type 2 diabetes. Diabetes Care 2002; 25: 1802-1806.
29. Goldman D. Lung dysfunction in diabetes. Diabetes Care 2003; 26: 1913-1918.
30. Kaminsky D. Spirometry and diabetes: Implications of reduced lung function. Diabetes Care 2004; 27: 837-838.
31. Davis A.W., Knuiman M., Kendall P., Grange V., Davis T. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care 2004; 27: 752-757.
32. Litonjua A., Lazarus R., Sparrow D., DeMolles D., Weiss S. Lung function in type 2 diabetes: the Normative Aging Study. Respir. Med. 2005; 99: 1583-1590.
33. Yeh H., Punjabi N.M., Wang N. i wsp. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2008; 31: 741-746.
34. Fletcher C., Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645-1648.
35. Klein B., Moss S., Klein R. i wsp. Peak expiratory flow rate: relationship to risk variables and martality: the Wisconsin Epidemiologic Study of diabetes retinopathy. Diabetes Care 2001; 24: 1967-1971.
36. Guvener N., Tutuncu S., Akacy S. i wsp. Alveolar gas exchange in patients with type 2 diabetes mellitus. Endocrine Journal 2003; 50: 663-667.
37. Schuyler M., Niewoehner D., Inkley S. i wsp. Abnormal lung elasticity in juvenile diabetes mellitus. Am. Rev. Resp. Dis. 1976; 113: 37-41.
38. Schernthaner G., Haber F., Kummer F., Ludwig H. Lung elasticity in juvenile-onset diabetes mellitus. Am. Rev. Respir. Dis. 1977; 116: 544-546.
39. Sandler M., Bunn A.E, Stewart R.I. Pulmonary function in young insulin-dependent diabetic subject. Chest 1986; 90: 670-675.
40. Villa M.P., Montesano M., Barreto M. i wsp. Diffusing capacity for carbon monoxide in children with type 1 diabetes. Diabetologia 2004; 47: 1931-1935.
41. Fuso L., Basso S., De Rosa M. i wsp. Postural variations of pulmonary diffusing capacity in insulin-dependent diabetes mellitus. Chest 1996; 110: 1009-1013.
42. Strojek K., Ziora D., Sroczyński J. i wsp. Objawy płucne późnych powikłań cukrzycowych. Pneumonol. Alergol. Pol. 1993; 61: 166-170.
43. Kuziemski K., Górska L., Słomiński W. i wsp. Znaczenie DLCO w wykrywaniu mikroangiopatii płucnej. Doniesienie wstȩapne. Pneumonol. Alergol. Pol. 2008; 76 (supl 1.): 43A.
44. Mori H., Okubo M., Okamura M. i wsp. Abnormalities of pulmonary function in patients with non-insulin-dependent diabetes mellitus. Intern. Med. 1992; 31: 189-193.
45. Davis T., Knuiman M., Kendall P. i wsp. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Res. Clin. Pract. 2000; 50: 153-159.
46. Engstrom G., Janzon L. Risk developing diabetes is inversely related to lung function: a population-based cohorty study. Diabetes Med. 2002; 19: 167-170.
47. Ljubic S., Matelko Z., Car N. i wsp. Reduction of diffusion capacity for carbon monoxidate in diabetic patients. Chest 1998; 114: 1033-1035.
48. Klein B., Moss S., Klein R. i wsp. Peak expiratory flow rate: relationship to risk variables and mortality: the Wisconsin Epidemiologic Study of diabetes retinopathy. Diabetes Care 2001; 24: 1967-1971.
49. Ford E. Body mass index, diabetes and C-reactive protein among U.S. adults. Diabetes Care 1999; 22: 1971-1977.
50. Elasy T. Diabetes and C-reactive protein. Clin. Diabet. 2007; 25: 1-2.
51. Hollander P.A., Blonde L., Rowe R. i wsp. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: Results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2356-2362.
52. Gerber R.A., Cappelleri J.C., Kourides I.A. i wsp. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes. A randomized controlled trial. Diabetes Care 2001; 24: 1556-1559.
53. De Fronzo R.A., Bergenstal R.M., Cefalu W.T. i wsp. Efficacy of inhaled insulin in patients with type II diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28: 1922-1928.
54. Lenzer J. Inhaled insulin is approved in Europe and United States. BMJ 2006; 332: 321-324.
55. Becker R.H.A., Sha S., Frick A.D., Fountaine R.J. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 2006; 29: 277-282.
56. Liu M.C., Riese R.J., Van Gundy K. Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes. Eur. Respir. J. 2008; 32: 180-188.
57. Skyler J.S., Jovanovic L., Klioze S., Reis J., Duggan W. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007; 30: 579-585.
58. Quattrin T., Belanger A., Bohannon N.J.V. i wsp. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622-2627.
59. Hsia C., Raskin F. The diabetic lung: relevance off alveolar microangiopathy for the use of inhaled insulin. Am. J. Med. 2005; 118: 205-211.
60. Nathan M.D. Counterpoint: No time to inhale: arguments against inhaled insulin in 2007. Diabetes Care 2007; 30: 442-443.